BX News & Analysis
4 articles
Market Mood
Blackstone Mortgage (BX) Q1 2026 Report: 98% Performing Loans
In Q1 2026, Blackstone Mortgage (BX) reported that 98% of its loans are performing, indicating strong asset quality. The company deployed $0.5 billion during this period, reflecting its commitment to active investment strategies. These figures are crucial as they suggest stability in revenue-generating capabilities and could impact investor confidence positively. The performance metrics may enhance BX's attractiveness to investors and influence its stock performance moving forward.
Read More
Blackstone (BX) Files for IPO of Data Center Acquisition Firm
Blackstone (BX) has filed for an initial public offering (IPO) for its data center acquisition firm. The details of the number of shares or value have not been disclosed. This filing is significant as it indicates Blackstone's continued investment in the growing data center market, which could attract investor interest. The data center sector is expanding rapidly, reflecting ongoing demand for cloud services and information technology infrastructure.
Read More
Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)
Senator Angus King Jr. (I-Maine) disclosed selling several stocks on February 13, 2026, including Autodesk (ADSK), Blackstone (BX), Eli Lilly (LLY), Meta Platforms (META), Microsoft (MSFT), Netflix (NFLX), On Holding (ONON), PayPal Holdings (PYPL), and Uber Technologies (UBER), with each transaction amounting to $1,000 to $15,000. All of these trades were marked as full sales of his positions. King's stock transactions total approximately $1.8 million since 2014, comprising around 125 trades. The senator still holds several other positions in his portfolio, which were not part of this sale.
Read More
Blackstone (BX) Closes $6.3bn Largest Life Sciences Fund Ever
Blackstone (BX) raised $6.3bn, marking the largest ever private funding investment round focused on life sciences. This capital will support the firm's BXLS platform, which aims to aid drug and medical technology development. Over the past year, BXLS has provided nearly $2bn in funding to companies, including $700m to MSD for an antibody-drug conjugate and $400m to Teva for inflammatory bowel diseases. The recent funding highlights ongoing investor interest in life sciences amidst challenging economic conditions.
Read More